U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula Fe.S2
Molecular Weight 119.975
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of FERROUS DISULFIDE

SMILES

[Fe++].[S-][S-]

InChI

InChIKey=NIFIFKQPDTWWGU-UHFFFAOYSA-N
InChI=1S/Fe.S2/c;1-2/q+2;-2

HIDE SMILES / InChI
Molecular Formula H2S2
Molecular Weight 66.146
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula Fe
Molecular Weight 55.845
Charge 2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/3541174 | https://books.google.ru/books?id=7mxyBgAAQBAJ&pg=PA13&lpg=PA13&dq=%22ferrous+iodide%22+anemia&source=bl&ots=ZGyFhUiJZ4&sig=IZOhRVaGmlwX7GcqgoE6rnCsCa4&hl=ru&sa=X&ved=0ahUKEwjYu7PCyYHUAhWiQpoKHR6cCfcQ6AEIUjAJ#v=onepage&q=%22ferrous%20iodide%22&f=false

There is no information about biological and pharmacological application of Iron(II) fluoride (also known as ferrous fluoride). It is known, that this substance is used to catalyze some organic reactions.

Originator

Approval Year

1921
1468
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
Not Provided
511
Unknown

Approved Use

Unknown
Palliative
Not Provided
511
Unknown

Approved Use

Unknown
Primary
Approved
8583
Ferro Sanol Duodenal

Approved Use

Ferro Sanol is an iron substitute in case of latent or manifest iron deficiency with and without development of anaemia.
Curative
Approved
8583
RADIOGARDASE

Approved Use

Insoluble Prussian blue is indicated for treatment of patients with known or suspected internal contamination with radioactive cesium and/or radioactive or non-radioactive thallium to increase their rates of elimination.

Launch Date

2003
PubMed

PubMed

TitleDatePubMed
Reactivity enhancement of iron sulfide nanoparticles stabilized by sodium alginate: Taking Cr (VI) removal as an example.
2017-07-05
Continuous sulfidogenic wastewater treatment with iron sulfide sludge oxidation and recycle.
2017-05-01
Atomic Layer Deposition of Iron Sulfide and Its Application as a Catalyst in the Hydrogenation of Azobenzenes.
2017-03-13
Synthesis of phosphabenzenes by an iron-catalyzed [2+2+2] cycloaddition reaction of diynes with phosphaalkynes.
2015-06-22
A practical and successful desensitization protocol for immediate hypersensitivity reactions to iron salts.
2014
Effect of abomasal ferrous lactate infusion on phosphorus absorption in lactating dairy cows.
2013-07
Tolerability of different oral iron supplements: a systematic review.
2013-04
Endothelial dysfunction and inflammation induced by iron oxide nanoparticle exposure: Risk factors for early atherosclerosis.
2011-06-10
The effect of iron treatment on adhesion molecules in patients with iron deficiency anemia.
2010-12
Bioleaching of heavy metals from sewage sludge by indigenous iron-oxidizing microorganisms using ammonium ferrous sulfate and ferrous sulfate as energy sources: a comparative study.
2009-11-15
Reversal of multidrug resistance by magnetic Fe3O4 nanoparticle copolymerizating daunorubicin and 5-bromotetrandrine in xenograft nude-mice.
2009
Decreased treatment failure rates following duodenal release ferrous glycine sulfate in iron deficiency anemia associated with autoimmune gastritis and Helicobacter pylori gastritis.
2007
Determination of water in ferrous lactate by near infrared reflectance spectroscopy with a fibre-optic probe.
1997-10
[Historical notes on the therapy of depression].
1986-11-22
[FERROUS ASPARTATE IN THERAPY].
1964-01-01
Clinical appraisal of drugs with special reference to a new chelate hematinic.
1957-07-11
[Ferrous lactate as an oral iron preparation for therapeutic use].
1954-11-27
THE USE OF FERROUS GLUCONATE IN THE TREATMENT OF HYPOCHROMIC ANEMIA.
1937-07
FERROUS IODIDE AND LINOLEIC ACID IN VITAMIN A DEFICIENCY. A REPLY TO CERTAIN CRITICISMS.
1932-11-11
THE ADMINISTRATION OF FERROUS IODIDE AND LINOLEIC ACID TO RATS DEPRIVED OF VITAMIN A.
1932-09-30
FERROUS IODIDE AS A SUBSTITUTE FOR VITAMIN A IN RATS.
1932-07-01
Patents

Patents

CN105565963
37
US20020127665
37
US2009028810
37
US20150202224
37
US2877253
37
US3091626
37
US5534268
37
US6407138
37
US8080520
37
US8802114
37

Sample Use Guides

In Vivo Use Guide
Adults should usually take one capsule a day. In cases of pronounced iron deficiency, adults can be given a dosage 2 to 3 times higher at the beginning of therapy. A daily dose of more than 5 mg Fe2+/kg body weight should in-well founded exceptional cases not be exceeded.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Mon Mar 31 21:36:01 GMT 2025
Edited
by admin
on Mon Mar 31 21:36:01 GMT 2025
Record UNII
132N09W4PR
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
HYDROPYRITE
Preferred Name English
FERROUS DISULFIDE
Common Name English
MARCASITE
Common Name English
IRON DISULFIDE (FES2)
Common Name English
IRON PYRITE
Systematic Name English
PYRITE
Systematic Name English
MARCASITE (FES2)
Common Name English
PYRITE (FES2)
Common Name English
IRON DISULFIDE
Systematic Name English
IRON PYRITE (FES2)
Common Name English
Pyrite [WHO-DD]
Common Name English
Code System Code Type Description
MESH
C011342
Created by admin on Mon Mar 31 21:36:01 GMT 2025 , Edited by admin on Mon Mar 31 21:36:01 GMT 2025
PRIMARY
CHEBI
86471
Created by admin on Mon Mar 31 21:36:01 GMT 2025 , Edited by admin on Mon Mar 31 21:36:01 GMT 2025
PRIMARY
RXCUI
1544140
Created by admin on Mon Mar 31 21:36:01 GMT 2025 , Edited by admin on Mon Mar 31 21:36:01 GMT 2025
PRIMARY
DAILYMED
132N09W4PR
Created by admin on Mon Mar 31 21:36:01 GMT 2025 , Edited by admin on Mon Mar 31 21:36:01 GMT 2025
PRIMARY
SMS_ID
100000172235
Created by admin on Mon Mar 31 21:36:01 GMT 2025 , Edited by admin on Mon Mar 31 21:36:01 GMT 2025
PRIMARY
EPA CompTox
DTXSID801014311
Created by admin on Mon Mar 31 21:36:01 GMT 2025 , Edited by admin on Mon Mar 31 21:36:01 GMT 2025
PRIMARY
ECHA (EC/EINECS)
215-167-7
Created by admin on Mon Mar 31 21:36:01 GMT 2025 , Edited by admin on Mon Mar 31 21:36:01 GMT 2025
ALTERNATIVE
CAS
1317-66-4
Created by admin on Mon Mar 31 21:36:01 GMT 2025 , Edited by admin on Mon Mar 31 21:36:01 GMT 2025
ALTERNATIVE
FDA UNII
132N09W4PR
Created by admin on Mon Mar 31 21:36:01 GMT 2025 , Edited by admin on Mon Mar 31 21:36:01 GMT 2025
PRIMARY
PUBCHEM
123110
Created by admin on Mon Mar 31 21:36:01 GMT 2025 , Edited by admin on Mon Mar 31 21:36:01 GMT 2025
PRIMARY
ECHA (EC/EINECS)
235-106-8
Created by admin on Mon Mar 31 21:36:01 GMT 2025 , Edited by admin on Mon Mar 31 21:36:01 GMT 2025
PRIMARY
CAS
12068-85-8
Created by admin on Mon Mar 31 21:36:01 GMT 2025 , Edited by admin on Mon Mar 31 21:36:01 GMT 2025
PRIMARY
CAS
1309-36-0
Created by admin on Mon Mar 31 21:36:01 GMT 2025 , Edited by admin on Mon Mar 31 21:36:01 GMT 2025
ALTERNATIVE
Related Record Type Details
Structure of FERROUS CATION
ACTIVE MOIETY
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966